QSA congratulates Autolus for achieving its historic milestone dosing the first patient with its pioneering BOBCAT trial of obecabtagene autoleucel (obe-cel), a ‘one-time’ immunotherapy treatment for progressive multiple sclerosis (PMS). QSA is providing advanced imaging analytics in support of this groundbreaking work.
Read the postNews
News
Company news, research and events from Queen Square Analytics.
2026
2025
2024
2023
2022
Planning a neurology trial?
Tell us about your study and the imaging questions behind it.